PPT-GU CONNECT PARP inhibitors in Prostate Cancer

Latest developments Prof Neeraj Agarwal MD Director Genitourinary Oncology Program Huntsman Cancer Institute University of Utah USA MARCH 2022 PARPi polyADP ribose polymerase inhibitors. Norm D. Smith, M.D.. Associate Professor. Co-Director. Urologic Oncology. University of Chicago. United States Preventive Services Task Force (USPSTF). USPSTF Warns Against Blood Test For Prostate Cancer. . Julian Mander . RPH Urology. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. PARP Inhibitors: What Do We know?. PARP Inhibitors: What Do We Know? (cont). PARP Inhibitors: What Don't We Know ?. SOLO-1: Study Rationale and Design. [a]. Primary Endpoint and Other . R. esults. Time to Second Progression or Death (. Program Overview . Discussion Outline. DNA Repair. ABCs of DNA Repair. DNA Repair Defects in Cancer. DNA Repair Defects Can Be an Achilles' Heel. Synthetic Lethality and Cancer DNA Repair Defects. Increased Sensitivity of . actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Mansoor Raza Mirza. NSGO: Nordic Society of Gynaecological Oncology. Five-year . survival. 15%. 30%. 40%. ?50%?. First use . of . cisplatin. First use . of . carboplatin. First use . of . Paclitaxel . First reports . of. bevacizumab. Positive evidence . for weekly paclitaxel in first line. Joel Brothers. 10/4/2016. Understand the indications and benefits of bisphosphonates in metastatic disease: . Breast Cancer. Prostate Cancer. Multiple Myeloma. Other Solid Malignancies. 2) Understand the role of bisphosphonates/. The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. If you decide not to get screened, you can always change your mind later. If you decide to get screened, it does not mean you have to go to the next step. You should discuss each step with your docto Clinical implementation of testing and PARP. i. monotherapy, and the patient journey for prostate cancer patients. Dr Neal Shore. , . MD, FACS. Carolina Urologic Research Center and Chief Medical Officer for Genesis Care, USA. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening..